NCT06677762View on ClinicalTrials.gov

Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Pancreatic Cancer
Interventions
PROCEDURE

Irreversible electroporation

Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06677762 - Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter